細胞免疫療法市場：タイプ別、適応症別、技術タイプ別、最終用途別-2025-2030年の世界予測

細胞免疫療法市場は、2023年に112億3,000万米ドルと評価され、2024年には140億2,000万米ドルに達すると予測され、CAGR 25.34％で成長し、2030年には546億米ドルに達すると予測されています。

がん治療の先駆的分野である細胞免疫療法は、T細胞などの体内の免疫細胞を活用してがん細胞を標的にして破壊します。このアプローチは、従来の治療法に比べて副作用が少なく、高度に調整された治療法を提供できる可能性があるため、非常に重要です。アンメット・キーワードの必要性は、アンメット・メディカル・ニーズ、特に従来の治療法に耐性のあるがんに対処する能力にあります。用途は主に白血病やリンパ腫などの血液悪性腫瘍を中心とした腫瘍学であるが、固形腫瘍や慢性感染症にも急速に拡大しています。最終用途は、病院、がん研究センター、バイオテクノロジー企業などです。市場は、がん罹患率の上昇、遺伝子工学の技術的進歩、研究開発への投資の増加によって牽引されています。主な成長要因としては、精密医療に対する需要の高まりとともに、政府による新治療法の支援や承認が挙げられます。最近のFDAによるCAR T細胞療法の承認は、大きな機会を裏付けるものであり、利害関係者にNK細胞療法や併用療法のような次世代技術への投資を促しています。しかし、複雑な製造工程、高額な治療費、規制上のハードルなどの課題も残っています。また、治療に関連した毒性の可能性や、患者が治療を受けられるようになるまでのリードタイムの長さといった限界もあります。技術革新は、治療法の安全性と有効性の改善、製造コストの削減、患者へのアクセスの向上に焦点を当てるべきです。同種移植の既製ソリューションや個別化治療レジメンの開発研究は、有意義な進歩をもたらす可能性があります。市場は依然としてダイナミックで、急速な技術革新と競合情勢を特徴としており、共同研究や買収が頻繁に成長の軌道を形成しています。企業は、戦略的パートナーシップを構築し、技術シフトに適応し続けることで、こうした動向を活用しなければならないです。そうすることで、課題を克服し、この重要な分野で強固なポートフォリオを構築することができます。

市場力学：急速に進化する細胞免疫療法市場の主要市場インサイトを公開

細胞免疫療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんと先進細胞療法の流行
  • 細胞療法の研究開発に対する政府の積極的な取り組み
  • 腫瘍浸潤リンパ球（TIL）療法と人工T細胞受容体（TCR）療法の普及拡大
• 市場抑制要因
  • 機器や治療法の初期コストの高さ
• 市場機会
  • 細胞免疫療法に関する技術の進歩と新製品
  • 様々な細胞ベースの免疫療法薬の承認の増加
• 市場の課題
  • 製品リコールと厳しい規制当局の承認

ポーターの5つの力：細胞免疫療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞免疫療法市場における外部からの影響の把握

外部マクロ環境要因は、細胞免疫療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞免疫療法市場における競合情勢の把握

細胞免疫療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞免疫療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞免疫療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨細胞免疫療法市場における成功への道筋を描く

細胞免疫療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんの蔓延と高度な細胞ベースの治療法
    • 細胞治療の研究開発に対する政府の好ましい取り組み
    • 腫瘍浸潤リンパ球（TIL）療法と改変T細胞受容体（TCR）療法の普及率の増加
  • 抑制要因
    • 機器や治療法の初期費用が高い
  • 機会
    • 細胞免疫療法の技術進歩と新製品
    • さまざまな細胞ベースの免疫療法薬の承認が増加
  • 課題
    • 製品リコールと厳格な規制承認
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 細胞免疫療法市場：タイプ別

• CAR T細胞療法
• 樹状細胞療法
• NK細胞療法
• 腫瘍浸潤リンパ球療法

第7章 細胞免疫療法市場適応症別

• B細胞悪性腫瘍
• 肝臓がん
• 前立腺がん
• 腎細胞がん

第8章 細胞免疫療法市場テクノロジーの種類別

• サイトカインと免疫調節剤
• モノクローナル抗体

第9章 細胞免疫療法市場：最終用途別

• がん研究所
• 病院

第10章 南北アメリカの細胞免疫療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の細胞免疫療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの細胞免疫療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adaptimmune Therapeutics PLC
• Adicet Bio, Inc.
• Apac Biotech Private Limited
• AstraZeneca PLC
• Atara Biotherapeutics, Inc.
• Bio-Rad Laboratories, Inc.
• Bristol-Myers Squibb Company
• Celyad Oncology SA
• Corning Incorporated
• Dendreon Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Glycostem Therapeutics B.V.
• Immatics N.V.
• Inovio Pharmaceuticals, Inc.
• Iovance Biotherapeutics, Inc.
• Johnson & Johnson Services, Inc.
• JW Therapeutics（Shanghai）Co., Ltd.
• Lonza Group Ltd.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Tessa Therapeutics Ltd.

LIST OF FIGURES

• FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES & IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CANCER INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 191. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Cellular Immunotherapy Market was valued at USD 11.23 billion in 2023, expected to reach USD 14.02 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 54.60 billion by 2030.

Cellular immunotherapy, a pioneering field within cancer treatment, leverages the body's immune cells, such as T-cells, to target and destroy cancerous cells. This approach is critical due to its potential to offer highly tailored therapies with fewer side effects compared to conventional treatments. The necessity of cellular immunotherapy lies in its capacity to address unmet medical needs, particularly for cancers that are resistant to traditional therapies. Applications are primarily in oncology, focusing on hematological malignancies like leukemia and lymphoma, but it's rapidly expanding into solid tumors and chronic infections. End-use encompasses hospitals, cancer research centers, and biotech firms. The market is driven by a rise in cancer prevalence, technological advancements in genetic engineering, and increasing investments in R&D. Key growth factors include governmental support and approval of new therapies, alongside the escalating demand for precision medicine. Recent FDA approvals of CAR T-cell therapies underscore significant opportunities, urging stakeholders to invest in next-gen technologies like NK-cell therapies and combination treatments. However, challenges persist, such as complex manufacturing processes, high treatment costs, and regulatory hurdles. Limitations also include potential therapy-related toxicity and long lead times to patient availability. Innovation should focus on improving the safety and efficacy of therapies, reducing production costs, and enhancing patient accessibility. Research into developing allogeneic, off-the-shelf solutions and personalized treatment regimens could offer meaningful advancements. The market remains dynamic, characterized by rapid innovation and a competitive landscape, with collaborations and acquisitions frequently shaping growth trajectories. Companies must capitalize on these trends by building strategic partnerships and remaining adaptive to technological shifts. By doing so, they can navigate challenges and ensure robust portfolio development in this critical field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cellular Immunotherapy Market

The Cellular Immunotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cancer and advanced cell based therapies
  • Favorable government initiatives for cellular therapies R&D
  • Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
• Market Restraints
  • High initial costs of devices and therapies
• Market Opportunities
  • Technological advancements and new products for cellular immunotherapy
  • Increasing approvals of different cell-based immunotherapy drugs
• Market Challenges
  • Product recalls and stringent regulatory approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cellular Immunotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cellular Immunotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cellular Immunotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cellular Immunotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cellular Immunotherapy Market

A detailed market share analysis in the Cellular Immunotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cellular Immunotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cellular Immunotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cellular Immunotherapy Market

A strategic analysis of the Cellular Immunotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd..

Market Segmentation & Coverage

This research report categorizes the Cellular Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, and Tumor-Infiltrating Lymphocytes Therapy.
• Based on Indication, market is studied across B-Cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
• Based on Technology Type, market is studied across Cytokines & Immunomodulators and Monoclonal Antibodies.
• Based on End-Use, market is studied across Cancer Institutes and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancer and advanced cell based therapies
    • 5.1.1.2. Favorable government initiatives for cellular therapies R&D
    • 5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
  • 5.1.2. Restraints
    • 5.1.2.1. High initial costs of devices and therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements and new products for cellular immunotherapy
    • 5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Product recalls and stringent regulatory approvals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cellular Immunotherapy Market, by Type

• 6.1. Introduction
• 6.2. CAR T-Cell Therapy
• 6.3. Dendritic Cell Therapy
• 6.4. NK Cell Therapy
• 6.5. Tumor-Infiltrating Lymphocytes Therapy

7. Cellular Immunotherapy Market, by Indication

• 7.1. Introduction
• 7.2. B-Cell Malignancies
• 7.3. Liver Cancer
• 7.4. Prostate Cancer
• 7.5. Renal Cell Carcinoma

8. Cellular Immunotherapy Market, by Technology Type

• 8.1. Introduction
• 8.2. Cytokines & Immunomodulators
• 8.3. Monoclonal Antibodies

9. Cellular Immunotherapy Market, by End-Use

• 9.1. Introduction
• 9.2. Cancer Institutes
• 9.3. Hospitals

10. Americas Cellular Immunotherapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cellular Immunotherapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cellular Immunotherapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptimmune Therapeutics PLC
• 2. Adicet Bio, Inc.
• 3. Apac Biotech Private Limited
• 4. AstraZeneca PLC
• 5. Atara Biotherapeutics, Inc.
• 6. Bio-Rad Laboratories, Inc.
• 7. Bristol-Myers Squibb Company
• 8. Celyad Oncology SA
• 9. Corning Incorporated
• 10. Dendreon Pharmaceuticals LLC
• 11. Eli Lilly and Company
• 12. F. Hoffmann-La Roche AG
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline PLC
• 15. Glycostem Therapeutics B.V.
• 16. Immatics N.V.
• 17. Inovio Pharmaceuticals, Inc.
• 18. Iovance Biotherapeutics, Inc.
• 19. Johnson & Johnson Services, Inc.
• 20. JW Therapeutics (Shanghai) Co., Ltd.
• 21. Lonza Group Ltd.
• 22. Merck KGaA
• 23. Novartis AG
• 24. Pfizer Inc.
• 25. Tessa Therapeutics Ltd.